1 cognitive-behavioral/pharmacologic group (CB-PHARM), 2) attention-control/pharmacologic group, or 3)

2 ; pediatrics; children; pain assessment; non-pharm*; analges*.

3  receiving either C-ECT (10 treatments) or C-Pharm for 6 months.

4 ks compared with 6.7 +/- 4.6 weeks for the C-Pharm group (P = .13).

5 er state and trait anxiety scores for the CB-PHARM group at the 15-month followup.

6                                     In the C-Pharm group, 31.6% experienced disease relapse, 46.3% co

7 depression, compared between the C-ECT and C-Pharm groups.

8 d distributions can be found at http://actin.pharm.mssm.edu/AVIS2.

9  be found in the user manual at http://actin.pharm.mssm.edu/AVIS2/manual.pdf.

10     Genes2FANs is available at: http://actin.pharm.mssm.edu/genes2FANs.

11 se is freely available online at: http://amp.pharm.mssm.edu/lib/chea.jsp.

12 KEA system is freely available at http://amp.pharm.mssm.edu/lib/kea.jsp

13 and is free for academic use from http://amp.pharm.mssm.edu/maayan-lab/gate.htm

14 rted as cost-effective in a previous review (Pharm Pract (Granada), 2014;12:493), but methods used to

15 active site of Chk-1 kinase, using the FlexX-Pharm program.

16 is free and downloadable at http://mljohnson.pharm.virginia.edu/home.html.

17                             Both C-ECT and C-Pharm were shown to be superior to a historical placebo